I'm certainly keeping an open mind about positive outcomes from this but I'm not holding my breath, nor getting excited.
I've been to their clinic and was underwhelmed.
The press report is just hype. We hear these types of reports all the time and they don't necessarily mean much. Maybe it is grant funding time and they are trying to get publicity.
Sounds like very early days in the development of a diagnostic test. Patent applications don't mean anything. This is done automatically very early in the process just in case something comes out of it.
I've read the letter to the editor (This is a mini-paper. It gets you a publication when you don't have enough new information for a full paper. Maybe they are planning on presenting the data at a conference and want to make sure they have prior publication rights to it.), also the quote from the press report describing what the test is about.
It does sound like the test could be based on the differences in SNPs described in the paper. Sounds like they could be looking for these differences as translated into the ion-channel receptors on the surface of white blood cells. I could be reading the wrong thing into these vague quotes of course but that's how it seems to me.
The main problem lies in the reported SNP study. It is very small (100 patients) with very basic statistics. It probably means very little. We have just been reminded in the recent series from
@Simon on the Power and Pitfalls of Omics of Prof George Davey Smith's expert critique of these types of studies. To mean anything they need to be big (1000s) and analysis needs to be much more sophisticated.